Pharmaceuticals, Biotechnology and Life Sciences
BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company…
– Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) – – Cohort 1 Data in OASIS…
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies…
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical…
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201…
Company to host conference call at 5:00 p.m. ETMENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ:…
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of…
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart…
PORTLAND, Ore., May 14, 2021 (GLOBE NEWSWIRE) — Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (“Golden Leaf” or the “Company”), operating…
EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are: Treatment naïveSwitching from C5…